Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

August 1, 2024

Conditions
Cardiac SurgeryLow Ejection Fraction
Interventions
DRUG

levosemindan

In common practice the loading dose is omitted as it is associated with hypotension.9 Usual dose range: 0.05 to 0.2 microg/kg/min. Dose based on actual body weight up to a maximum of 120 kg.5 Commence infusion at 0.05 microg/kg/min. If the initial rate is tolerated, consider increasing the maintenance rate to 0.1 microg/kg/min after 60 minutes. If the patient remains haemodynamically stable, further increase the dose to 0.2 microg/kg/min for the remainder of the infusion.

DRUG

adrenaline,noreadrenaline,dopamine and doputamine

adrenaline:\*4 9 %$ 0 \*\*\*\*8\*4\* 9 : ,- 4 - \*4 9 \* C % F\*4 9 9 9 noreadrenaline:# \*4 9 C % 9 F 9 9 \*4\* Q\*4 9 9 dopamine:9 \* C % 9 F 9 9 ) \* 9 9 dobutamine:9 \* C % F 9 9 9 \* 9 9

Trial Locations (1)

44519

cardiothorathic surgery department -faculty of medecine-zagazig univeristy-Egypt, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV

NCT06784570 - Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction | Biotech Hunter | Biotech Hunter